Skip to main content
Grant Details

Grant Number: 1R03CA078195-01 Interpret this number
Primary Investigator: Fedi, Paolo
Organization: Mount Sinai School Of Medicine
Project Title: Validation of Erbb-3 Immunostaining in Breast Tumor
Fiscal Year: 1998
Back to top


Abstract

DESCRIPTION (Applicant's Description) Evidence for biological synergism of plasma-membrane tyrosine kinase receptors erbB-3 and erbB-2 in model systems and human breast tumor cell lines raises the possibility that coexpression of these receptors may play a role in tumorigenesis and cell proliferation. Thus, identifying coexpressing erbB-2 and erbB-3 receptors in tumor specimens will provide greater specificity, and might identify a subpopulation of patients with different outcome and chemotherapeutic potential. However, the existing clinical studies are weak, and the data on expression of erbB-3 in breast tumors are inconsistent. In particular, the disagreement among studies with regard to cytoplasmic versus membrane staining is troubling. A major contributing factor is the poorly characterized antibody used in all studies. The goal of this proposal is to validate reagents for detection of erbB-3 expression by immunohistochemistry in paraffin sections of breast tumors. Therefore, our specific aims are: (1) to perform immunostaining of erbB-3 in transfected and tumor cell lines using five different erbB-3 antibodies, (2) to localize the cell fraction in which erbB-3 resides in these cell lines, and (3) to compare the pattern of staining of those antibodies in tumor specimens. Using this knowledge, we can establish a valid protocol for quantitating erbB-3 in breast cancer an evaluating its etiologic prognostic significance.

Back to top


Publications

Error Notice

If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.

Please contact us if this error persists.

We apologize for the inconvenience.
- The DCCPS Team.


Back to Top